What's in Guerbet's pipeline?

Guerbet has 14 drugs in our index: 11 marketed, 0 filed, 2 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Guerbet's portfolio?

Top competitors by shared drug class: Seoul National University Hospital, Bracco Diagnostics, Inc, Bayer, GE HealthCare, GE Healthcare.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/guerbet.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Guerbet — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Guerbet pipeline: 11 marketed, 0 filed, 2 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

11 marketed 0 filed 2 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Dotarem	GADOTERATE MEGLUMINE	marketed	gadoterate meglumine		Other	2013-01-01
Ioxitol	IOXILAN	marketed	Radiographic Contrast Agent		Other	1995-01-01
Gadovist®/Gadavist®	Gadovist®/Gadavist®	marketed	Gadolinium-based contrast agent	Water proton relaxation (T1 relaxation enhancement)	Diagnostic Imaging
DOTAREM	DOTAREM	marketed	Gadolinium-based contrast agent	Water proton relaxation (T1 and T2 relaxation times)	Diagnostic Imaging
Dotarem®-enhanced MRI	Dotarem®-enhanced MRI	marketed	Gadolinium-based contrast agent	Water proton relaxation (T1 relaxation time)	Diagnostic Imaging
Lipiodol Ultra Fluid with surgical glues	Lipiodol Ultra Fluid with surgical glues	marketed	Radiographic contrast agent / Hemostatic agent		Surgery / Interventional Radiology
Xenetix	Xenetix	marketed			Other
Elucirem	Elucirem	marketed			Other
Ioversol 320 mgI/mL	Ioversol 320 mgI/mL	marketed	Non-ionic iodinated contrast medium		Diagnostic Imaging
Xenetix-CT perfusion imaging	Xenetix-CT perfusion imaging	marketed	Iodinated contrast medium		Diagnostic Imaging
Iodixanol 320 mgI/mL	Iodixanol 320 mgI/mL	marketed	Iso-osmolar contrast medium (IOCM)		Diagnostic Imaging
Gadoterate meglumine (Dotarem)	Gadoterate meglumine (Dotarem)	phase 3	Gadolinium-based contrast agent (GBCA)	Water proton relaxation (non-receptor mediated)	Diagnostic Imaging

Therapeutic area mix

Diagnostic Imaging · 8
Other · 4
Surgery / Interventional Radiology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Seoul National University Hospital · 2 shared drug classes
Bracco Diagnostics, Inc · 2 shared drug classes
Bayer · 2 shared drug classes
GE HealthCare · 1 shared drug class
GE Healthcare · 1 shared drug class
Insel Gruppe AG, University Hospital Bern · 1 shared drug class
Paracelsus Medical University · 1 shared drug class
Shanghai Shengdi Pharmaceutical Co., Ltd · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Guerbet:

Cite this brief

Drug Landscape (2026). Guerbet — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/guerbet. Accessed 2026-06-10.